forecast
Psilocybin therapy next in queue for depression
Psilocybin therapy is next in the queue, with a phase 3 trial underway sponsored by Compass Pathways for treatment-resistant depression—building on the first psilocybin-for-depression trial at Imperial College London published in 2016—with FDA submission forecast around 2026.
forecastpending
Speaker
Robin Carhart-HarrisEvidence Quote
“there's a phase three trial currently underway sponsored by compass pathways and there the indication is treatment resistant depression”
Created: 6/14/2026, 2:20:20 AM
Your notes
Loading notes...